Small Fiber Neuropathy
Purpose of Review This narrative review aims to summarize advances in the field of small fiber neuropathy made over the last decade, with emphasis on novel research highlighting the distinctive features of SFN. Recent Findings While the management of SFNs is ideally aimed at treating the underlying...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Strand, N. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. corrected publication 2022 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Current Review of Pain - Current Medicine Group, 1998, 26(2022), 6 vom: 06. Apr., Seite 429-438 |
|---|---|
| Übergeordnetes Werk: |
volume:26 ; year:2022 ; number:6 ; day:06 ; month:04 ; pages:429-438 |
| Links: |
|---|
| DOI / URN: |
10.1007/s11916-022-01044-8 |
|---|
| Katalog-ID: |
SPR047071893 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR047071893 | ||
| 003 | DE-627 | ||
| 005 | 20230507185516.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220522s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11916-022-01044-8 |2 doi | |
| 035 | |a (DE-627)SPR047071893 | ||
| 035 | |a (SPR)s11916-022-01044-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Strand, N. |e verfasserin |0 (orcid)0000-0002-9489-2550 |4 aut | |
| 245 | 1 | 0 | |a Small Fiber Neuropathy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. corrected publication 2022 | ||
| 520 | |a Purpose of Review This narrative review aims to summarize advances in the field of small fiber neuropathy made over the last decade, with emphasis on novel research highlighting the distinctive features of SFN. Recent Findings While the management of SFNs is ideally aimed at treating the underlying cause, most patients will require pain control via multiple, concurrent therapies. Herein, we highlight the most up-to-date information for diagnosis, medication management, interventional management, and novel therapies on the horizon. Summary Despite the prevalence of small fiber neuropathies, there is no clear consensus on guidelines specific for the treatment of SFN. Despite the lack of specific guidelines for SFN treatment, the most recent general neuropathic pain guidelines are based on Cochrane studies and randomized controlled trials (RCTs) which have individually examined therapies used for the more commonly studied SFNs, such as painful diabetic neuropathy and HIV neuropathy. The recommendations from current guidelines are based on variables such as number needed to treat (NNT), safety, ease of use, and effect on quality of life. | ||
| 650 | 4 | |a Pain |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Chronic pain |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neuropathy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neuropathic pain |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pain medicine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pain management |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Wie, C. |4 aut | |
| 700 | 1 | |a Peck, J. |4 aut | |
| 700 | 1 | |a Maita, M. |4 aut | |
| 700 | 1 | |a Singh, N. |4 aut | |
| 700 | 1 | |a Dumbroff, J. |4 aut | |
| 700 | 1 | |a Tieppo Francio, V. |4 aut | |
| 700 | 1 | |a Murphy, M. |4 aut | |
| 700 | 1 | |a Chang, K. |4 aut | |
| 700 | 1 | |a Dickerson, D. M. |4 aut | |
| 700 | 1 | |a Maloney, J. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current Review of Pain |d Current Medicine Group, 1998 |g 26(2022), 6 vom: 06. Apr., Seite 429-438 |w (DE-627)SPR023001666 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2022 |g number:6 |g day:06 |g month:04 |g pages:429-438 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11916-022-01044-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_252 | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2022 |e 6 |b 06 |c 04 |h 429-438 | ||
| author_variant |
n s ns c w cw j p jp m m mm n s ns j d jd f v t fv fvt m m mm k c kc d m d dm dmd j m jm |
|---|---|
| matchkey_str |
strandnwiecpeckjmaitamsinghndumbroffjtie:2022----:mlfbrer |
| hierarchy_sort_str |
2022 |
| publishDate |
2022 |
| allfields |
10.1007/s11916-022-01044-8 doi (DE-627)SPR047071893 (SPR)s11916-022-01044-8-e DE-627 ger DE-627 rakwb eng Strand, N. verfasserin (orcid)0000-0002-9489-2550 aut Small Fiber Neuropathy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. corrected publication 2022 Purpose of Review This narrative review aims to summarize advances in the field of small fiber neuropathy made over the last decade, with emphasis on novel research highlighting the distinctive features of SFN. Recent Findings While the management of SFNs is ideally aimed at treating the underlying cause, most patients will require pain control via multiple, concurrent therapies. Herein, we highlight the most up-to-date information for diagnosis, medication management, interventional management, and novel therapies on the horizon. Summary Despite the prevalence of small fiber neuropathies, there is no clear consensus on guidelines specific for the treatment of SFN. Despite the lack of specific guidelines for SFN treatment, the most recent general neuropathic pain guidelines are based on Cochrane studies and randomized controlled trials (RCTs) which have individually examined therapies used for the more commonly studied SFNs, such as painful diabetic neuropathy and HIV neuropathy. The recommendations from current guidelines are based on variables such as number needed to treat (NNT), safety, ease of use, and effect on quality of life. Pain (dpeaa)DE-He213 Chronic pain (dpeaa)DE-He213 Neuropathy (dpeaa)DE-He213 Neuropathic pain (dpeaa)DE-He213 Pain medicine (dpeaa)DE-He213 Pain management (dpeaa)DE-He213 Wie, C. aut Peck, J. aut Maita, M. aut Singh, N. aut Dumbroff, J. aut Tieppo Francio, V. aut Murphy, M. aut Chang, K. aut Dickerson, D. M. aut Maloney, J. aut Enthalten in Current Review of Pain Current Medicine Group, 1998 26(2022), 6 vom: 06. Apr., Seite 429-438 (DE-627)SPR023001666 nnns volume:26 year:2022 number:6 day:06 month:04 pages:429-438 https://dx.doi.org/10.1007/s11916-022-01044-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_73 GBV_ILN_252 AR 26 2022 6 06 04 429-438 |
| spelling |
10.1007/s11916-022-01044-8 doi (DE-627)SPR047071893 (SPR)s11916-022-01044-8-e DE-627 ger DE-627 rakwb eng Strand, N. verfasserin (orcid)0000-0002-9489-2550 aut Small Fiber Neuropathy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. corrected publication 2022 Purpose of Review This narrative review aims to summarize advances in the field of small fiber neuropathy made over the last decade, with emphasis on novel research highlighting the distinctive features of SFN. Recent Findings While the management of SFNs is ideally aimed at treating the underlying cause, most patients will require pain control via multiple, concurrent therapies. Herein, we highlight the most up-to-date information for diagnosis, medication management, interventional management, and novel therapies on the horizon. Summary Despite the prevalence of small fiber neuropathies, there is no clear consensus on guidelines specific for the treatment of SFN. Despite the lack of specific guidelines for SFN treatment, the most recent general neuropathic pain guidelines are based on Cochrane studies and randomized controlled trials (RCTs) which have individually examined therapies used for the more commonly studied SFNs, such as painful diabetic neuropathy and HIV neuropathy. The recommendations from current guidelines are based on variables such as number needed to treat (NNT), safety, ease of use, and effect on quality of life. Pain (dpeaa)DE-He213 Chronic pain (dpeaa)DE-He213 Neuropathy (dpeaa)DE-He213 Neuropathic pain (dpeaa)DE-He213 Pain medicine (dpeaa)DE-He213 Pain management (dpeaa)DE-He213 Wie, C. aut Peck, J. aut Maita, M. aut Singh, N. aut Dumbroff, J. aut Tieppo Francio, V. aut Murphy, M. aut Chang, K. aut Dickerson, D. M. aut Maloney, J. aut Enthalten in Current Review of Pain Current Medicine Group, 1998 26(2022), 6 vom: 06. Apr., Seite 429-438 (DE-627)SPR023001666 nnns volume:26 year:2022 number:6 day:06 month:04 pages:429-438 https://dx.doi.org/10.1007/s11916-022-01044-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_73 GBV_ILN_252 AR 26 2022 6 06 04 429-438 |
| allfields_unstemmed |
10.1007/s11916-022-01044-8 doi (DE-627)SPR047071893 (SPR)s11916-022-01044-8-e DE-627 ger DE-627 rakwb eng Strand, N. verfasserin (orcid)0000-0002-9489-2550 aut Small Fiber Neuropathy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. corrected publication 2022 Purpose of Review This narrative review aims to summarize advances in the field of small fiber neuropathy made over the last decade, with emphasis on novel research highlighting the distinctive features of SFN. Recent Findings While the management of SFNs is ideally aimed at treating the underlying cause, most patients will require pain control via multiple, concurrent therapies. Herein, we highlight the most up-to-date information for diagnosis, medication management, interventional management, and novel therapies on the horizon. Summary Despite the prevalence of small fiber neuropathies, there is no clear consensus on guidelines specific for the treatment of SFN. Despite the lack of specific guidelines for SFN treatment, the most recent general neuropathic pain guidelines are based on Cochrane studies and randomized controlled trials (RCTs) which have individually examined therapies used for the more commonly studied SFNs, such as painful diabetic neuropathy and HIV neuropathy. The recommendations from current guidelines are based on variables such as number needed to treat (NNT), safety, ease of use, and effect on quality of life. Pain (dpeaa)DE-He213 Chronic pain (dpeaa)DE-He213 Neuropathy (dpeaa)DE-He213 Neuropathic pain (dpeaa)DE-He213 Pain medicine (dpeaa)DE-He213 Pain management (dpeaa)DE-He213 Wie, C. aut Peck, J. aut Maita, M. aut Singh, N. aut Dumbroff, J. aut Tieppo Francio, V. aut Murphy, M. aut Chang, K. aut Dickerson, D. M. aut Maloney, J. aut Enthalten in Current Review of Pain Current Medicine Group, 1998 26(2022), 6 vom: 06. Apr., Seite 429-438 (DE-627)SPR023001666 nnns volume:26 year:2022 number:6 day:06 month:04 pages:429-438 https://dx.doi.org/10.1007/s11916-022-01044-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_73 GBV_ILN_252 AR 26 2022 6 06 04 429-438 |
| allfieldsGer |
10.1007/s11916-022-01044-8 doi (DE-627)SPR047071893 (SPR)s11916-022-01044-8-e DE-627 ger DE-627 rakwb eng Strand, N. verfasserin (orcid)0000-0002-9489-2550 aut Small Fiber Neuropathy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. corrected publication 2022 Purpose of Review This narrative review aims to summarize advances in the field of small fiber neuropathy made over the last decade, with emphasis on novel research highlighting the distinctive features of SFN. Recent Findings While the management of SFNs is ideally aimed at treating the underlying cause, most patients will require pain control via multiple, concurrent therapies. Herein, we highlight the most up-to-date information for diagnosis, medication management, interventional management, and novel therapies on the horizon. Summary Despite the prevalence of small fiber neuropathies, there is no clear consensus on guidelines specific for the treatment of SFN. Despite the lack of specific guidelines for SFN treatment, the most recent general neuropathic pain guidelines are based on Cochrane studies and randomized controlled trials (RCTs) which have individually examined therapies used for the more commonly studied SFNs, such as painful diabetic neuropathy and HIV neuropathy. The recommendations from current guidelines are based on variables such as number needed to treat (NNT), safety, ease of use, and effect on quality of life. Pain (dpeaa)DE-He213 Chronic pain (dpeaa)DE-He213 Neuropathy (dpeaa)DE-He213 Neuropathic pain (dpeaa)DE-He213 Pain medicine (dpeaa)DE-He213 Pain management (dpeaa)DE-He213 Wie, C. aut Peck, J. aut Maita, M. aut Singh, N. aut Dumbroff, J. aut Tieppo Francio, V. aut Murphy, M. aut Chang, K. aut Dickerson, D. M. aut Maloney, J. aut Enthalten in Current Review of Pain Current Medicine Group, 1998 26(2022), 6 vom: 06. Apr., Seite 429-438 (DE-627)SPR023001666 nnns volume:26 year:2022 number:6 day:06 month:04 pages:429-438 https://dx.doi.org/10.1007/s11916-022-01044-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_73 GBV_ILN_252 AR 26 2022 6 06 04 429-438 |
| allfieldsSound |
10.1007/s11916-022-01044-8 doi (DE-627)SPR047071893 (SPR)s11916-022-01044-8-e DE-627 ger DE-627 rakwb eng Strand, N. verfasserin (orcid)0000-0002-9489-2550 aut Small Fiber Neuropathy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. corrected publication 2022 Purpose of Review This narrative review aims to summarize advances in the field of small fiber neuropathy made over the last decade, with emphasis on novel research highlighting the distinctive features of SFN. Recent Findings While the management of SFNs is ideally aimed at treating the underlying cause, most patients will require pain control via multiple, concurrent therapies. Herein, we highlight the most up-to-date information for diagnosis, medication management, interventional management, and novel therapies on the horizon. Summary Despite the prevalence of small fiber neuropathies, there is no clear consensus on guidelines specific for the treatment of SFN. Despite the lack of specific guidelines for SFN treatment, the most recent general neuropathic pain guidelines are based on Cochrane studies and randomized controlled trials (RCTs) which have individually examined therapies used for the more commonly studied SFNs, such as painful diabetic neuropathy and HIV neuropathy. The recommendations from current guidelines are based on variables such as number needed to treat (NNT), safety, ease of use, and effect on quality of life. Pain (dpeaa)DE-He213 Chronic pain (dpeaa)DE-He213 Neuropathy (dpeaa)DE-He213 Neuropathic pain (dpeaa)DE-He213 Pain medicine (dpeaa)DE-He213 Pain management (dpeaa)DE-He213 Wie, C. aut Peck, J. aut Maita, M. aut Singh, N. aut Dumbroff, J. aut Tieppo Francio, V. aut Murphy, M. aut Chang, K. aut Dickerson, D. M. aut Maloney, J. aut Enthalten in Current Review of Pain Current Medicine Group, 1998 26(2022), 6 vom: 06. Apr., Seite 429-438 (DE-627)SPR023001666 nnns volume:26 year:2022 number:6 day:06 month:04 pages:429-438 https://dx.doi.org/10.1007/s11916-022-01044-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_73 GBV_ILN_252 AR 26 2022 6 06 04 429-438 |
| language |
English |
| source |
Enthalten in Current Review of Pain 26(2022), 6 vom: 06. Apr., Seite 429-438 volume:26 year:2022 number:6 day:06 month:04 pages:429-438 |
| sourceStr |
Enthalten in Current Review of Pain 26(2022), 6 vom: 06. Apr., Seite 429-438 volume:26 year:2022 number:6 day:06 month:04 pages:429-438 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Pain Chronic pain Neuropathy Neuropathic pain Pain medicine Pain management |
| isfreeaccess_bool |
false |
| container_title |
Current Review of Pain |
| authorswithroles_txt_mv |
Strand, N. @@aut@@ Wie, C. @@aut@@ Peck, J. @@aut@@ Maita, M. @@aut@@ Singh, N. @@aut@@ Dumbroff, J. @@aut@@ Tieppo Francio, V. @@aut@@ Murphy, M. @@aut@@ Chang, K. @@aut@@ Dickerson, D. M. @@aut@@ Maloney, J. @@aut@@ |
| publishDateDaySort_date |
2022-04-06T00:00:00Z |
| hierarchy_top_id |
SPR023001666 |
| id |
SPR047071893 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR047071893</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230507185516.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220522s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s11916-022-01044-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR047071893</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s11916-022-01044-8-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Strand, N.</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0002-9489-2550</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Small Fiber Neuropathy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. corrected publication 2022</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose of Review This narrative review aims to summarize advances in the field of small fiber neuropathy made over the last decade, with emphasis on novel research highlighting the distinctive features of SFN. Recent Findings While the management of SFNs is ideally aimed at treating the underlying cause, most patients will require pain control via multiple, concurrent therapies. Herein, we highlight the most up-to-date information for diagnosis, medication management, interventional management, and novel therapies on the horizon. Summary Despite the prevalence of small fiber neuropathies, there is no clear consensus on guidelines specific for the treatment of SFN. Despite the lack of specific guidelines for SFN treatment, the most recent general neuropathic pain guidelines are based on Cochrane studies and randomized controlled trials (RCTs) which have individually examined therapies used for the more commonly studied SFNs, such as painful diabetic neuropathy and HIV neuropathy. The recommendations from current guidelines are based on variables such as number needed to treat (NNT), safety, ease of use, and effect on quality of life.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pain</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chronic pain</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neuropathy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neuropathic pain</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pain medicine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pain management</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wie, C.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Peck, J.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maita, M.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Singh, N.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dumbroff, J.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tieppo Francio, V.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Murphy, M.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chang, K.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dickerson, D. M.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maloney, J.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Current Review of Pain</subfield><subfield code="d">Current Medicine Group, 1998</subfield><subfield code="g">26(2022), 6 vom: 06. Apr., Seite 429-438</subfield><subfield code="w">(DE-627)SPR023001666</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:26</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:6</subfield><subfield code="g">day:06</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:429-438</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s11916-022-01044-8</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_252</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">26</subfield><subfield code="j">2022</subfield><subfield code="e">6</subfield><subfield code="b">06</subfield><subfield code="c">04</subfield><subfield code="h">429-438</subfield></datafield></record></collection>
|
| author |
Strand, N. |
| spellingShingle |
Strand, N. misc Pain misc Chronic pain misc Neuropathy misc Neuropathic pain misc Pain medicine misc Pain management Small Fiber Neuropathy |
| authorStr |
Strand, N. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR023001666 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Small Fiber Neuropathy Pain (dpeaa)DE-He213 Chronic pain (dpeaa)DE-He213 Neuropathy (dpeaa)DE-He213 Neuropathic pain (dpeaa)DE-He213 Pain medicine (dpeaa)DE-He213 Pain management (dpeaa)DE-He213 |
| topic |
misc Pain misc Chronic pain misc Neuropathy misc Neuropathic pain misc Pain medicine misc Pain management |
| topic_unstemmed |
misc Pain misc Chronic pain misc Neuropathy misc Neuropathic pain misc Pain medicine misc Pain management |
| topic_browse |
misc Pain misc Chronic pain misc Neuropathy misc Neuropathic pain misc Pain medicine misc Pain management |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Current Review of Pain |
| hierarchy_parent_id |
SPR023001666 |
| hierarchy_top_title |
Current Review of Pain |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR023001666 |
| title |
Small Fiber Neuropathy |
| ctrlnum |
(DE-627)SPR047071893 (SPR)s11916-022-01044-8-e |
| title_full |
Small Fiber Neuropathy |
| author_sort |
Strand, N. |
| journal |
Current Review of Pain |
| journalStr |
Current Review of Pain |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
txt |
| container_start_page |
429 |
| author_browse |
Strand, N. Wie, C. Peck, J. Maita, M. Singh, N. Dumbroff, J. Tieppo Francio, V. Murphy, M. Chang, K. Dickerson, D. M. Maloney, J. |
| container_volume |
26 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Strand, N. |
| doi_str_mv |
10.1007/s11916-022-01044-8 |
| normlink |
(ORCID)0000-0002-9489-2550 |
| normlink_prefix_str_mv |
(orcid)0000-0002-9489-2550 |
| title_sort |
small fiber neuropathy |
| title_auth |
Small Fiber Neuropathy |
| abstract |
Purpose of Review This narrative review aims to summarize advances in the field of small fiber neuropathy made over the last decade, with emphasis on novel research highlighting the distinctive features of SFN. Recent Findings While the management of SFNs is ideally aimed at treating the underlying cause, most patients will require pain control via multiple, concurrent therapies. Herein, we highlight the most up-to-date information for diagnosis, medication management, interventional management, and novel therapies on the horizon. Summary Despite the prevalence of small fiber neuropathies, there is no clear consensus on guidelines specific for the treatment of SFN. Despite the lack of specific guidelines for SFN treatment, the most recent general neuropathic pain guidelines are based on Cochrane studies and randomized controlled trials (RCTs) which have individually examined therapies used for the more commonly studied SFNs, such as painful diabetic neuropathy and HIV neuropathy. The recommendations from current guidelines are based on variables such as number needed to treat (NNT), safety, ease of use, and effect on quality of life. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. corrected publication 2022 |
| abstractGer |
Purpose of Review This narrative review aims to summarize advances in the field of small fiber neuropathy made over the last decade, with emphasis on novel research highlighting the distinctive features of SFN. Recent Findings While the management of SFNs is ideally aimed at treating the underlying cause, most patients will require pain control via multiple, concurrent therapies. Herein, we highlight the most up-to-date information for diagnosis, medication management, interventional management, and novel therapies on the horizon. Summary Despite the prevalence of small fiber neuropathies, there is no clear consensus on guidelines specific for the treatment of SFN. Despite the lack of specific guidelines for SFN treatment, the most recent general neuropathic pain guidelines are based on Cochrane studies and randomized controlled trials (RCTs) which have individually examined therapies used for the more commonly studied SFNs, such as painful diabetic neuropathy and HIV neuropathy. The recommendations from current guidelines are based on variables such as number needed to treat (NNT), safety, ease of use, and effect on quality of life. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. corrected publication 2022 |
| abstract_unstemmed |
Purpose of Review This narrative review aims to summarize advances in the field of small fiber neuropathy made over the last decade, with emphasis on novel research highlighting the distinctive features of SFN. Recent Findings While the management of SFNs is ideally aimed at treating the underlying cause, most patients will require pain control via multiple, concurrent therapies. Herein, we highlight the most up-to-date information for diagnosis, medication management, interventional management, and novel therapies on the horizon. Summary Despite the prevalence of small fiber neuropathies, there is no clear consensus on guidelines specific for the treatment of SFN. Despite the lack of specific guidelines for SFN treatment, the most recent general neuropathic pain guidelines are based on Cochrane studies and randomized controlled trials (RCTs) which have individually examined therapies used for the more commonly studied SFNs, such as painful diabetic neuropathy and HIV neuropathy. The recommendations from current guidelines are based on variables such as number needed to treat (NNT), safety, ease of use, and effect on quality of life. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. corrected publication 2022 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_73 GBV_ILN_252 |
| container_issue |
6 |
| title_short |
Small Fiber Neuropathy |
| url |
https://dx.doi.org/10.1007/s11916-022-01044-8 |
| remote_bool |
true |
| author2 |
Wie, C. Peck, J. Maita, M. Singh, N. Dumbroff, J. Tieppo Francio, V. Murphy, M. Chang, K. Dickerson, D. M. Maloney, J. |
| author2Str |
Wie, C. Peck, J. Maita, M. Singh, N. Dumbroff, J. Tieppo Francio, V. Murphy, M. Chang, K. Dickerson, D. M. Maloney, J. |
| ppnlink |
SPR023001666 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s11916-022-01044-8 |
| up_date |
2024-07-04T01:44:09Z |
| _version_ |
1803610959644721152 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR047071893</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230507185516.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220522s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s11916-022-01044-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR047071893</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s11916-022-01044-8-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Strand, N.</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0002-9489-2550</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Small Fiber Neuropathy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. corrected publication 2022</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose of Review This narrative review aims to summarize advances in the field of small fiber neuropathy made over the last decade, with emphasis on novel research highlighting the distinctive features of SFN. Recent Findings While the management of SFNs is ideally aimed at treating the underlying cause, most patients will require pain control via multiple, concurrent therapies. Herein, we highlight the most up-to-date information for diagnosis, medication management, interventional management, and novel therapies on the horizon. Summary Despite the prevalence of small fiber neuropathies, there is no clear consensus on guidelines specific for the treatment of SFN. Despite the lack of specific guidelines for SFN treatment, the most recent general neuropathic pain guidelines are based on Cochrane studies and randomized controlled trials (RCTs) which have individually examined therapies used for the more commonly studied SFNs, such as painful diabetic neuropathy and HIV neuropathy. The recommendations from current guidelines are based on variables such as number needed to treat (NNT), safety, ease of use, and effect on quality of life.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pain</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chronic pain</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neuropathy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neuropathic pain</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pain medicine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pain management</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wie, C.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Peck, J.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maita, M.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Singh, N.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dumbroff, J.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tieppo Francio, V.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Murphy, M.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chang, K.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dickerson, D. M.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maloney, J.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Current Review of Pain</subfield><subfield code="d">Current Medicine Group, 1998</subfield><subfield code="g">26(2022), 6 vom: 06. Apr., Seite 429-438</subfield><subfield code="w">(DE-627)SPR023001666</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:26</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:6</subfield><subfield code="g">day:06</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:429-438</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s11916-022-01044-8</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_252</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">26</subfield><subfield code="j">2022</subfield><subfield code="e">6</subfield><subfield code="b">06</subfield><subfield code="c">04</subfield><subfield code="h">429-438</subfield></datafield></record></collection>
|
| score |
7.3998365 |